Did You Know? Beyond the Data

Defining and Treating High Risk HR-positive/HER2-Negative Early Breast Cancer

Hear perspectives of real-world evidence of recurrence risk with endocrine therapy alone, the prognostic impact of high-risk disease, and clinical evidence supporting adjuvant CDK4/6 inhibitors from Seth Wander, MD, PhD, of Harvard Medical School and Massachusetts General Hospital, and Kathryn Post, PhD, RN, ANP-BC, of Harvard Medical School and Mass General Brigham Cancer Institute.

CDK4/6 Inhibitors for Treatment of High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Addressing Tolerability to Maximize Treatment Persistence

We are pleased to announce Part 2 of the new 2-part series, Did You Know? Beyond the Data. Our second article, with video commentary by Hope Rugo, MD, and an accompanying infographic, presents clinical data and real-world evidence on treatment patterns and tolerability considerations for CDK4/6 inhibitors in patients with early breast cancer with high risk of recurrence. We invite you to explore this informative series, designed to empower healthcare professionals with actionable insights to improve patient outcomes.

The Impact of Underutilizing Adjuvant CDK4/6 Inhibitors in Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer

We are pleased to announce a new 2-part series, Did You Know? Beyond the Data. This article, with video commentary by Hope Rugo, MD, and an accompanying infographic, provides the latest clinical data and real-world evidence for consideration when treating early breast cancer patients with high risk of recurrence. We invite you to explore this informative series, designed to empower healthcare professionals with actionable insights to improve patient outcomes.

Did You Know? Beyond the Data

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.